Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

GLP-1 is the same hormone targeted by semaglutide and tirzepatide ... Others given the maximum daily dose of two 50mg tablets lost an average of 13.1 per cent, according to the findings presented ...